Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

Clinical trial NCT00779935 · COMPLETED

Trial details

NCT number: NCT00779935
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Spondylitis, Ankylosing

Start date: 2004-10-01
Primary completion: 2005-10-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.